Dynamic	O
Control	O
of	O
Enhancer	O
Repertoires	O
Drives	O
Lineage	O
and	O
Stage	O
-	O
Specific	O
Transcription	O
during	O
Hematopoiesis	O
.	O


Enhancers	O
are	O
the	O
primary	O
determinants	O
of	O
cell	O
identity	O
,	O
but	O
the	O
regulatory	O
components	O
controlling	O
enhancer	O
turnover	O
during	O
lineage	O
commitment	O
remain	O
largely	O
unknown	O
.	O


Here	O
we	O
compare	O
the	O
enhancer	O
landscape	O
,	O
transcriptional	O
factor	O
occupancy	O
,	O
and	O
transcriptomic	O
changes	O
in	O
human	O
fetal	O
and	O
adult	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	O
and	O
committed	O
erythroid	O
progenitors	O
.	O


We	O
find	O
that	O
enhancers	O
are	O
modulated	O
pervasively	O
and	O
direct	O
lineage	O
-	O
and	O
stage	O
-	O
specific	O
transcription	O
.	O


GATA2	O
-	O
to	O
-	O
GATA1	O
switch	O
is	O
prevalent	O
at	O
dynamic	O
enhancers	O
and	O
drives	O
erythroid	O
enhancer	O
commissioning	O
.	O


Examination	O
of	O
lineage	O
-	O
specific	O
enhancers	O
identifies	O
transcription	O
factors	O
and	O
their	O
combinatorial	O
patterns	O
in	O
enhancer	O
turnover	O
.	O


Importantly	O
,	O
by	O
CRISPR	O
/	O
Cas9	O
-	O
mediated	O
genomic	O
editing	O
,	O
we	O
uncover	O
functional	O
hierarchy	O
of	O
constituent	O
enhancers	O
within	O
the	O
SLC25A37	B-ENHANCER
super	I-ENHANCER
-	I-ENHANCER
enhancer	E-ENHANCER
.	O


Despite	O
indistinguishable	O
chromatin	O
features	O
,	O
we	O
reveal	O
through	O
genomic	O
editing	O
the	O
functional	O
diversity	O
of	O
several	O
GATA	O
switch	O
enhancers	O
in	O
which	O
enhancers	O
with	O
opposing	O
functions	O
cooperate	O
to	O
coordinate	O
transcription	O
.	O


Thus	O
,	O
genome	O
-	O
wide	O
enhancer	O
profiling	O
coupled	O
with	O
in	O
situ	O
enhancer	O
editing	O
provide	O
critical	O
insights	O
into	O
the	O
functional	O
complexity	O
of	O
enhancers	O
during	O
development	O
.	O
